Welcome to our dedicated page for Fulcrum Therapeutics SEC filings (Ticker: FULC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading a clinical-stage biotech filing can feel like decoding molecular biology. Fulcrum Therapeutics� 10-K is packed with gene-expression charts, DUX4 risk factors, and cash-runway tables that easily exceed 200 pages. Finding the latest losmapimod trial update or the cost of developing pociredir isn’t straightforward—and missing those details can skew valuation models.
Stock Titan solves that problem. Our AI engine breaks down every Fulcrum Therapeutics SEC filing—whether it’s a Fulcrum Therapeutics annual report 10-K simplified or a Fulcrum Therapeutics quarterly earnings report 10-Q filing—into concise highlights, then links directly to the full text on EDGAR. Need real-time alerts? We push Fulcrum Therapeutics Form 4 insider transactions real-time to your dashboard, so you know when executives buy or sell ahead of pivotal readouts. You can also skim an 8-K material events explained summary minutes after it posts.
Here’s what you can do on this page:
- Track Fulcrum Therapeutics insider trading Form 4 transactions and spot buying patterns before Phase 3 data drops.
- Compare R&D spend across quarters with an AI-annotated earnings report filing analysis.
- Review the proxy statement executive compensation section to see how milestones drive management bonuses.
- Use "understanding Fulcrum Therapeutics SEC documents with AI" guides to decode complex gene-regulation jargon.
Whether you’re modeling burn rate, watching for orphan-drug status updates, or verifying executive stock transactions Form 4, Stock Titan surfaces the insights buried deep inside each form—so you can act before the market does.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, reports shared beneficial ownership of 4,589,000 shares of Fulcrum Therapeutics common stock, representing 8.50% of the class based on 53,979,306 shares outstanding. The shares are held directly by Adage Capital Partners, L.P., with Adage acting as investment manager and Messrs. Atchinson and Gross identified as managing members of the related entities.
The filing shows no sole voting or dispositive power; all voting and disposition power is reported as shared. The reporting persons certify the holdings are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
FAQ
What is the current stock price of Fulcrum Therapeutics (FULC)?
What is the market cap of Fulcrum Therapeutics (FULC)?
